title: The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope.
abstract: CBD1 peptide (SLEQIWNNMTWMQWDK), corresponding to the consensus caveolin-1 binding domain in HIV-1 envelope glycoprotein gp41, elicits the production of antibodies that inhibit infection of primary CD4(+) T lymphocytes by various primary HIV-1 isolates. Here the immunogenicity of the CBD1 peptide was investigated in cynomolgus macaques using adjuvants that are acceptable for human use. In the first set of studies, macaques were immunized with the CBD1 peptide in association with muramyl dipeptide derivative MDP-Lys(L18) combined with the oil-in-water emulsion, MF-59. After five immunizations at 4 weeks interval, the antibody titer against the CBD1 peptide was found to be either medium, poor, weak or none, thus suggesting that the CBD1 immune response might be restricted by the major histocompatibility complex (MHC) class II molecules. In the second set of studies therefore, macaques were immunized with the CBD1 peptide in association with the 'promiscuous' T cell epitope from the tetanus toxin, either as free peptides or covalently linked with the dilysine linker using CpG ODN and Montanide ISA 51 as adjuvants. This latter immunization procedure boosted markedly the anti-CBD1 antibody response, since even the non-responders generated high-titered peptide-specific antibodies. Moreover, co-immunization of the CBD1 and the T helper epitope as free peptides seemed to be favorable for the production of neutralizing antibodies, with 50% inhibition of HIV-1 infection occurring at 300-400-fold dilution of the immune sera. Finally, neutralizing and non-neutralizing immune macaque sera could be differentiated by the profile of cross-reactivity with overlapping CBD1-related peptides in ELISA. Taken together, our results demonstrate that the CBD1 peptide is immunogenic in macaques and that an eventual MHC-restriction could be overcome by the administration with an appropriate T helper epitope.
authors.affiliation: UPR 2228 CNRS, Université Paris Descartes, 45 rue des Saints Pères, 75270 Paris Cedex 06, France.
authors.forename: Rima
authors.initials: R
authors.lastname: Benferhat
authors.forename: Frédéric
authors.initials: F
authors.lastname: Martinon
authors.forename: Bernard
authors.initials: B
authors.lastname: Krust
authors.forename: Roger
authors.initials: R
authors.lastname: Le Grand
authors.forename: Ara G
authors.initials: AG
authors.lastname: Hovanessian
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives / Q000276:immunology / Q000378:metabolism; D000276:Adjuvants, Immunologic; D000595:Amino Acid Sequence; D000818:Animals; D000917:Antibody Formation; D051242:Caveolin 1 / Q000276:immunology / Q000378:metabolism; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000276:immunology* / Q000378:metabolism; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007371:Interferon-gamma / Q000276:immunology / Q000378:metabolism; D008252:Macaca fascicularis / Q000276:immunology; D008285:Major Histocompatibility Complex / Q000276:immunology; D008297:Male; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010455:Peptides / Q000008:administration & dosage / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology / Q000378:metabolism / Q000821:virology; D013744:Tetanus Toxin / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; C539885:CBD1 peptide; D051242:Caveolin 1; D018984:Epitopes, T-Lymphocyte; D015700:HIV Envelope Protein gp41; D010455:Peptides; D013744:Tetanus Toxin; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D007371:Interferon-gamma